Odesivimab is a Zaire ebolavirus glycoprotein-directed human monoclonal antibody that is part of the fixed-dose combination atoltivimab/maftivimab/odesivimab that is used for the treatment of Zaire ebolavirus (Ebola virus).[1][2]
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | Zaire ebolavirus glycoprotein |
| Clinical data | |
| Pronunciation | oh" de siv' i mab |
| License data |
|
| Drug class | Monoclonal antibody |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6506H10024N1720O2030S42 |
| Molar mass | 146164.29 g·mol−1 |
References edit
- ^ "FDA Approves First Treatment for Ebola Virus". U.S. Food and Drug Administration (FDA) (Press release). 14 October 2020. Retrieved 14 October 2020.
This article incorporates text from this source, which is in the public domain.
- ^ "Regeneron's Antibody Cocktail REGN-EB3 (Inmazeb) is First FDA-Approved Treatment for Ebola (Zaire Ebolavirus)". Regeneron Pharmaceuticals Inc. (Press release). 14 October 2020. Retrieved 14 October 2020.
External links edit
- "Odesivimab". Drug Information Portal. U.S. National Library of Medicine.
- "Statement on a nonproprietary name adopted by the USAN Council USAN (FG-102) Odesivimab" (PDF).
 | This antiinfective drug article is a stub. You can help Wikipedia by expanding it. |